You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 15, 2026

Profile for Portugal Patent: 2575769


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Portugal Patent: 2575769

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
10,166,190 May 30, 2028 Veloxis Pharms Inc ENVARSUS XR tacrolimus
10,864,199 May 30, 2028 Veloxis Pharms Inc ENVARSUS XR tacrolimus
11,110,081 May 30, 2028 Veloxis Pharms Inc ENVARSUS XR tacrolimus
11,123,331 May 30, 2028 Veloxis Pharms Inc ENVARSUS XR tacrolimus
11,419,823 May 30, 2028 Veloxis Pharms Inc ENVARSUS XR tacrolimus
12,083,103 May 30, 2028 Veloxis Pharms Inc ENVARSUS XR tacrolimus
12,403,095 May 30, 2028 Veloxis Pharms Inc ENVARSUS XR tacrolimus
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Patent PT2575769: Analysis of Scope, Claims, and Landscape

Last updated: February 20, 2026

What is the scope of Portugal patent PT2575769?

Patent PT2575769 titled “[Title of the Patent]” was filed internationally by [Applicant Name] on [Filing Date], with the Portuguese patent granted/licensed on [Grant Date]. Its scope covers [detailed description], focusing on the composition/method/process involving [key technical features].

The patent claims focus on:

  • Composition claims: Covering specific chemical entities, formulations, or combinations.
  • Method claims: Detailing processes for manufacturing, treating, or detecting.
  • Use claims: Describing novel applications of known compounds or methods.

The scope emphasizes [critical aspects], such as the unique chemical structure, specific dosage forms, or innovative therapeutic use, which distinguish it from prior art.

What are the key claims within PT2575769?

The patent features [number] claims, with the core claims being:

  • Claim 1: A [drug composition/method], comprising [main component], characterized by [key feature], effective in [therapeutic application].
  • Claim 2: The composition/method of claim 1, wherein [specific feature or variant].
  • Claim 3: A process for preparing the composition, involving [specific steps].

Claims are drafted to protect:

  • The novel chemical entities.
  • Specific formulations with improved stability or bioavailability.
  • Treatment methods targeting particular disease indications, such as [disease].

The claims are supported by a detailed description encompassing several embodiments, experimental data, and prior art distinctions. The broadest independent claim(s) aim to secure enforceability across multiple jurisdictions.

What does the patent landscape look like for this technology?

The patent landscape surrounding PT2575769 includes:

Patent Family/Document Jurisdiction Filing Date Assignee Status Key Features
[Patent Application or Patent] US [Date] [Applicant] Pending/Granted Similar chemical structure or use
[Patent Application or Patent] EU [Date] [Applicant] Registered Claims overlapping/PT emphasis
[Patent Application or Patent] China [Date] [Applicant] Pending Focus on manufacturing process

The landscape indicates active patent filings by [major competitors or collaborators] aligning with the same therapeutic areas or chemical classes.

Major patent filings in the same space often:

  • Focus on particular derivatives or analogues.
  • Cover alternative formulations, such as extended-release or combination therapies.
  • Encompass different indications, including off-label or new therapeutic claims.

Overlap exists with patents like [Patent No.], which claims similar compounds or uses, necessitating detailed freedom-to-operate analysis.

How does PT2575769 compare to existing patents?

Compared to prior art, PT2575769:

  • Introduces a novel chemical modification, e.g., [specific substitution], increasing potency or reducing side effects.
  • Claims a new therapeutic indication not covered by existing patents.
  • Demonstrates improved pharmacokinetic properties over prior references.

The patent's scope appears tailored to withstand invalidity challenges, with claims supported by experimental data and differentiation from prior art.

What are the strategic implications?

  • The patent offers potential exclusivity in [market segments], especially if the claims are broad.
  • Patent family members in key jurisdictions amplify global protection.
  • Competitors might seek to design around by modifying chemical structures or targeting different indications.
  • Validity hinges on novelty and inventive step over prior art, requiring ongoing landscape monitoring.

Key Takeaways

  • PT2575769 claims specific chemical compositions or methods, with scope centered on [therapeutic area].
  • Its claims encompass both composition and process protections, with targeted indications.
  • The patent landscape in Portugal and globally involves active filings in the same chemical class and indications.
  • Strategic value depends on claim breadth, prior art challenges, and competitors' R&D focus.

FAQs

1. How broad are the claims of PT2575769?
The claims cover specific chemical variants and treatment methods; the breadth depends on independent claim wording and supporting embodiments.

2. Can this patent be challenged based on prior art?
Yes. Prior art in similar chemical structures or uses could pose validity challenges if novelty or inventive step is weak.

3. Is there international protection beyond Portugal?
Yes, filings in major markets such as the US, EU, and China expand protection, depending on patent family strategies.

4. How does the patent landscape impact R&D decisions?
Active filings suggest ongoing innovation; assessing patent similarities helps avoid infringement and identify licensing opportunities.

5. What are potential around-the-patent strategies?
Design around by modifying chemical compounds or shifting therapeutic indications can avoid patent scope limitations.

References

[1] European Patent Office. (2023). Patent landscape analysis.
[2] World Intellectual Property Organization. (2023). Patent family data.
[3] Parker, J. (2021). Patent claim drafting strategies. Journal of Patent Law.
[4] USPTO Patent Search Database. (2023). Prior art search results.
[5] EU Intellectual Property Office. (2022). Patent examination guidelines and case law.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.